Date: 2018-06-19
Type of information: Research agreement
Compound: 3D bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
Company: Poietis (France) Prometheus, division of skeletal tissue engineering of KU Leuven (Belgium)
Therapeutic area: Technology - Services - Regenerative medicine
Type agreement: research - development - R&D
Action mechanism: bioprinting
Disease:
Details:
- • On June 19, 2018, Poietis, a leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years collaborative research agreement focused on high-precision 3D bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
- Prometheus focuses on the bench-to-bedside clinical translation of increasingly sophisticated, tissue-engineered, ATMPs to patients in areas of high-unmet medical need with a focus in skeletal regeneration. Poietis has a specific background, expertise and interest in the use of 3D bioprinting of single cell suspensions into large, patterned tissue structures; and especially the application of laser-assisted bioprinting of multicellular micro-aggregates embedded in “bioinks” for the formation of layered cellular structures.
- The complementarity of both parties’ expertise will be a key point to address the challenges of tissue and organ manufacturing, and to translate tissue engineering research into accessible, affordable and reproducible tissue products. Based on previous successful common Proof-Of-Concept experiments the goal is to conduct pioneer pre-clinical work through a Collaborative Research Agreement on automated 3D bioprinting for skeletal ATMPs, with the aim to bringing designed living implants closer to the clinic.
- In 2017, the global tissue engineering market was estimated to grow from $4.7 billion in 2014 to $11.5 billion in 2022, the largest part thereof in orthopaedics, musculoskeletal and spine-related applications. Cost-effectiveness however is still a major bottleneck for successful commercialization of tissue engineered products.
Financial terms:
Latest news:
Is general: Yes
